We previously reported that loss of heterozygosity (LOH) on chromosome 9p21 correlates with poor prognosis of neuroblastoma and the p16 gene is not expressed in approximately two thirds of neuroblastoma cell lines. Here we demonstrated that p16 expression was induced by 5-aza-2-deoxycytidine treatment in cell lines with 5' CpG island methylation but not in cell lines without methylation. Furthermore, the cell cycle of neuroblastoma cell lines signi®cantly delayed with accumulation of cells in G1 phase by transfection of a wild-type p16 expression vector. These results indicate that p16 is inactivated in part by DNA methylation and its expression is involved in the growth of neuroblastoma cells in vitro. To assess the biological and clinical signi®cance of p16 expression in primary tumors, we undertook immunohistochemical analysis in 74 paran sections of neuroblastomas. p16 protein was undetectable in 45 of 74 cases (61%) and lack of p16 expression signi®cantly correlated with poor prognosis of patients and advanced stage of the disease. There was no correlation between loss of p16 expression and N-myc ampli®cation in these tumors. These results indicate that inactivation of the p16 gene is involved in the progression of neuroblastoma independently of N-myc ampli®cation.
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Introduction
Neuroblastoma is a tumor of neural crest origin that comprises 8 ± 10% of all childhood malignancies and causes 15% of cancer-related deaths in children (Matthay, 1995) . The tumor arises anywhere in the sympathetic nervous system and most frequently in the adrenalmedulla and paraspinal ganglia (Brodeur and Castleberry, 1995) . The best characterized genetic alteration associated with prognosis of neuroblastoma is ampli®cation of the N-myc gene (Brodeur et al., 1984) . High levels of TRK and Ha-ras expression were favorable prognostic markers in neuroblastoma (Nakagawara et al., 1992; Tanaka et al., 1995) . However, expression of these genes inversely correlates with N-myc ampli®cation, indicating that TRK and Ha-ras are not prognostic factors independently of N-myc ampli®cation (Nakagawara et al., 1992; Tanaka et al., 1995) . It was also reported that loss of heterozygosity (LOH) on chromosome 1p correlates with poor prognosis of neuroblastoma (Schleiermacher et al., 1994; Takeda et al., 1994) . However, 1p LOH is also associated with N-myc ampli®cation (Schleiermacher et al., 1994; Takeda et al., 1994) . This result suggested that both of these genetic changes exist in the dependent pathway for progression of neuroblastoma. However, since N-myc ampli®cation and 1p LOH occur in approximately a half of advanced neuroblastomas, it has been suggested that N-myc and 1p independent pathways exist in progression of neuroblastoma. Previously we demonstrated that chromosomes 2q, 9p and 18q were frequently deleted in neuroblastoma (Takita et al., 1995) . In particular, LOH on chromosome 9p including the p16 gene locus signi®cantly correlated with shortened survival of neuroblastoma patients independently of N-myc ampli®cation. Although p16 mutations occur rarely in neuroblastoma, the p16 gene was not expressed in two-thirds (13/19) of neuroblastoma cell lines, and methylation of the 5'CpG island in the p16 gene was detected in approximately 40% (5/13) of cell lines lacking p16 expression (Takita et al., 1997) . These results suggested that silencing of the p16 gene is associated with progression of neuroblastoma and is in part due to DNA methylation in neuroblastoma cells. Therefore, we assessed the role of p16 gene expression in the growth of neuroblastoma cells in vitro and the clinical behavior of neuroblastoma in vivo. It was shown here that forced p16 expression had an eect to suppress cell cycle progression in the G1 phase in neuroblastoma cells and the lack of p16 expression signi®cantly correlated with poor prognosis of patients and stage progression independently of N-myc ampli®cation. These results indicated that p16 is in a pathway of growth regulation in neuroblastoma cells and silencing of p16 gene expression is associated with more malignant phenotypes of neuroblastoma. Methylation of the 5'CpG island in the p16 gene was detected in approximately 40% of primary neuroblastomas lacking p16 expression, indicating that silencing of p16 expression is in part due to DNA methylation of the gene in vivo as well as in vitro.
Results

p16 gene expression induced by 5-aza-2-deoxycytidine in neuroblastoma cells
We previously showed that the p16 gene is not expressed in 13 of 19 (68%) neuroblastoma cell lines (Takita et al., 1997) . Among the 13 cell lines, the SmaI site within exon 1 was methylated in ®ve cell lines, NB9, NB19, LAN2, SCMCN4, and SCMCN5 (Takita et al., 1997) . By a PCR-based methylation assay using three methylation-sensitive enzymes, FunDII, HpaII and SacII, it was revealed that regions other than the SmaI site within exon 1 of the p16 gene were methylated in two other cell lines, LAN5 and KP-N-NS (data not shown). In total, seven of the 13 (54%) cell lines were shown to be methylated in the CpG island of the p16 gene. To elucidate whether hypermethylation of the p16 gene blocked gene expression in neuroblastoma cells, we subjected all cell lines to 3 days exposure of either 0.5 or 1.0 mM of 5-aza-2-deoxycytidine. Treatment with 0.5 mM of 5-aza-2-deoxycytidine was sucient for induction of p16 protein expression in all the seven cell lines in which the CpG island was methylated ( Figure 1 , Table 1 ). However, p16 expression was not induced in six cell lines in which hypermethylation of the CpG island was not detected. Thus, p16 expression was blocked by DNA methylation in a subset of neuroblastoma cells.
Eect of p16 expression on the growth of neuroblastoma cells
To determine the eect of p16 expression on the growth of neuroblastoma cells, we transfected the p16 expression vector pCDKN2WT or the control vector P114L into neuroblastoma cell lines, NB19, LAN2 and NB69, in which the p16 gene was not expressed. Methylation of the p16 gene was detected in NB19 and LAN2 cells but not in NB69 cells. After 48 h of transfection, cells were harvested and expression of exogenous p16 protein was examined by Western blot analysis. As shown in Figure 2 , p16 protein was detected in all these cell lines. Then we evaluated the eect of exogenous p16 protein expression on the cell cycle of these cell lines by¯ow cytometric analysis. Cells expressing high levels of exogenous p16 gene were detected by virtue of their high¯orescent intensity. As summarized in Table 2 , wild-type p16 expression signi®cantly increased the number of cells in G1 phase and decreased the number of cells in S and G2+M phases in all the three cell lines examined. In contrast, no G1 arrest was observed in the cells with mutant p16 expression. This result indicated that G1 arrest was *It was previously shown that the p16 gene is not expressed in these cell lines (Takita et al., 1997) Figure 1 Re-expression of transcriptionally silenced p16 after treatment with 5-aza-2-deoxycytidine in neuroblastoma cell lines. Western blot analysis of NB9, NB19, LAN2 and SCMCN4 cell lines harvested following 72 h incubation with control media (7) and 0.5 mM 5-aza-2-deoxycytidine (+). TGW cell line, which expressed abundant p16 protein, was used as a positive control for p16 expression (®rst lane) 
Relationship of loss of p16 expression with clinicopathological and molecular ®ndings in neuroblastoma
To assess the biological signi®cance of p16 gene inactivation in vivo, we performed immunohistochemical analysis using the JC8 anti-p16 mouse monoclonal antibody (Burns et al., 1998) . Speci®city of this antibody was con®rmed by the immunohistochemical staining of four neuroblastoma cell lines (Figure 3 ), since we previously showed that p16 is expressed in LAN1 and TGW and not expressed in LAN2 and NB69 (Takita et al., 1997) . The majority of LAN1 and TGW cells showed strong staining for the anti-p16 antibody, although the intensities of staining were dierent among the cells, probably due to the growth condition in each cell. In contrast, nearly all LAN2 cells and the majority of NB69 cells showed negative staining for the antibody. Thus, we concluded that the signal is speci®c for p16 expression. Then we performed immunohistochemical analysis using paraf®n sections of 74 neuroblastoma cases. Since the ratio of p16-positive NB69 cells was less than 10%, the p16 immunoreactivity was tentatively categorized into two groups; tumors with more than 10% of p16-positive cells were positive, and tumors with less than 10% of p16-positive cells were negative. Tumors showed considerable heterogeneity in the proportion of p16-positive cells. Most of p16 positive tumors showed a pattern of distinct diuse staining for the anti-p16 antibody, although the intensities of staining were dierent among the cells (Figure 4a and b). The pattern of staining in those tumors was similar to that in the p16-positive neuroblastoma cell lines. Among the p16-positive tumors, four tumors showed a pattern of mosaic staining for the anti-p16 antibody ( Figure 4c ). Both the area of p16-positive tumor cells and that of p16-negative tumor cells were present in the tissue specimens of those cases. However, overall most of the tumors showed relatively high populations of p16-positive cells; that is, more than 40% of the cells were p16-positive. The remaining 45 tumors (61%) were negative for p16, and p16 negative tumors showed extremely low population of p16-positive cells. We next analysed the association of p16 expression in the tumors with biological and clinical parameters; age, stage, result of screening, N-myc ampli®cation and survival. All patients were followed-up for at least 11 months and up to 141 months. The mean follow-up periods of patients with and without p16 expression in tumors were 85 and 73 months, respectively. The median ranges of survival of these patients were 71 and 51 months, respectively. Loss of p16 expression was signi®cantly associated with stage of the disease (with stage III, P=0.026 and stage IV, P=0.007) by Fisher's exact test and survival of the patients (P=0.002) by log rank test (Table 3) . Twenty-two of 45 patients (49%) lacking p16 expression died within 5 years, whereas only two of 29 patients (7%) with p16 expression died within this period (Figure 4 ). Although age and N-myc ampli®cation have been known as signi®cant prognostic factors in neuroblastoma (Tsuda et al., 1987; Tonini, 1993) , loss of p16 expression was not correlated with age and N-myc ampli®cation.
To further assess the prognostic signi®cance of p16 expression in neuroblastoma, multivariate analysis of survival was performed by p16 expression, genotype of N-myc, age (51 and 51), and stage (I+II+IVs, III, and IV) as covariates ( Table 4) . As reported previously, these factors were signi®cant associated with poor survival in our 74 patients by univariate analysis (Table 4) . However, by multivariate analysis, only N-myc and stage showed signi®cant associations with poor survival (P=0.0016 and P=0.0001, respectively), and p16 expression and age showed no signi®cant associations. Thus, N-myc ampli®cation and stage would be more distinct and independent prognostic factors of neuroblastoma than p16 expression and age. Then, to assess whether lack of p16 expression is a prognostic genetic marker of neuro- (a and b) , the majority of the cells showed strong nuclear and cytoplasmic staining for the anti-p16 antibody, although the intensities of staining were dierent among the cells. (c) nearly all cells showed negative nuclear and cytoplasmic staining for the antibody. (d) the majority of the cells showed negative nuclear and cytoplasmic staining, but a few cells showed strong nuclear and cytoplasmic staining for the antibody (original magni®cation;6200) p16 expression associated with the growth and prognosis in neuroblastoma J Takita et al blastoma independently of N-myc ampli®cation, multivariate analysis of survival was performed by p16 expression and N-myc ampli®cation as covariates (Table 4) , and univariate analysis was performed only in patients without N-myc ampli®cation. Signi®cant association was observed in both p16 expression and N-myc ampli®cation (P=0.027 and P=0.0001, respectively). Among 62 patients without N-myc amplification in the tumors, 14 of 38 (37%) of patients without p16 expression died whereas only one of 24 (4%) of patients with p16 expression died within 5 years. Thus, loss of p16 expression signi®cantly correlated with unfavorable outcome even among patients without Nmyc ampli®cation (P=0.014).
Association of p16 expression with p16 methylation and 9p LOH in neuroblastoma cells
Previously we examined LOH at chromosome 9p21 including the p16 gene locus in 38 of the 74 cases analysed in this study (Takita et al., 1997) . LOH was detected in 12 of the 38 cases and not in the remaining 26 cases We examined these 38 cases for methylation of the p16 gene by a PCR-based methylation assay using the FunDII and SmaI enzymes. Methylation was detected in nine of the 38 cases. Twenty-four of 38 (63%) cases were p16 negative in their tumor cells by immunohistochemical analysis. Then, association of p16 expression with methylation and 9p LOH was examined (Table 5 ). All nine tumors with p16 methylation lost p16 expression, and signi®cant association was detected between p16 expression and p16 methylation (P=0.0001). Five of nine tumors with p16 methylation showed 9p LOH, and there was no correlation between 9p LOH and p16 methylation (P=0.417). Only one of 12 tumors with 9p LOH were positive for p16 expression, and the remaining 11 tumors with 9p LOH were negative. p16 expression was signi®cantly associated with 9p LOH (P=0.002).
Discussion
Previously, we reported that LOH on chromosome 9p including the p16 gene locus was signi®cantly associated with unfavorable outcome of neuroblastoma patients independently of N-myc ampli®cation (Takita et al., 1997) . Thus, we further examined for mutations and expression of the p16 gene in primary neuroblastomas as well as neuroblastoma cell lines. Although homozygous deletions and point mutations of the p16 gene rarely occur in neuroblastoma (Beltinger et al., 1995; Takita et al., 1997) , p16 expression was not detected in various neuroblastoma cell lines (13/19) and p16 methylation was detected in approximately 40% (5/13) of cell lines lacking p16 expression (Takita et al., 1997) . These results suggested that silencing of p16 expression is involved in the progression of neuroblastoma and methylation of the p16 gene is one of the mechanisms for silencing of p16 expression. To determine whether 5'CpG island methylation blocked p16 expression in neuroblastoma cells, we tested whether the p16 gene was re-expressed by 5-aza-2-doxycytidine treatment. All seven cell lines that displayed hypermethylation of the p16 gene reexpressed p16 protein by treatment of 5-aza-2-deoxycytidine, indicating that the 5'CpG island hypermethylation is a direct cause of p16 silencing in neuroblastoma cells. In contrast, p16 expression was not induced by 5-aza-2-deoxycytidine in the cell lines without methylation of the p16 gene, suggesting that these cell lines lost p16 expression through dierent pathways from methylation of the gene.
There have been several reports showing that induction of p16 gene expression resulted in inhibition of cell cycle progression and decrease in the growth rate of cancer cells (Fueyo et al., 1996; Wu et al., 1996; Adachi et al., 1997) . In this study, a signi®cant degree of G1 arrest was induced in neuroblastoma cell lines lacking p16 expression with and without 5'CpG island methylation by transfection of a wild-type p16 vector. This result indicates that functional inactivation of the p16 gene contributes to cell cycle progression in neuroblastoma. Thus, as in the case of non-small cell lung carcinoma and glioma, the p16 gene would be a critical tumor suppressor gene whose inactivation is involved in the growth of neuroblastoma.
It has been suggested that p16 gene alterations occur after in vitro selection during adaptation to grow in cell culture. Therefore, to determine whether loss of p16 gene products occurs in primary tumors and whether it plays an important role in the genesis and/or progression of neuroblastoma in vivo, we performed an immunohistochemical analysis of p16 protein in 74 primary neuroblastomas. There were a number of tumors in which p16 protein was not expressed, indicating that loss of p16 expression occurs not only in cultured cells but also in primary tumors with relatively high incidence. Furthermore, loss of p16 expression signi®cantly correlated with advanced stage of the disease and shortened survival of patients, indicating that p16 expression can be a prognostic marker in neuroblastoma. To assess whether p16 expression is a useful prognostic marker for neuroblastoma independently of other prognostic factors, we performed multivariate analysis of survival with p16 expression and several other prognostic factors as covariates. Although, stage and N-myc ampli®cation were more signi®cant prognostic factors, p16 expression was also an useful prognostic marker in neuroblastoma independently of N-myc ampli®cation. Recently, it was reported that loss of p16 expression signi®cantly correlates with poor prognosis of patients with melanoma (Reed et al., 1995) , non-small cell lung carcinoma (Nakagawa et al., 1995) , malignant mesothelioma (Kratzke et al., 1995) . The present result is in good agreement with those ®ndings. Thus, inactivation of the p16 gene would be an essential step for the progression of neuroblastoma. It was previously reported that TRK and Ha-ras expression correlates with favorable outcome in neuroblastoma and inversely correlates with N-myc ampli®cation (Nakagawara et al., 1992; Tanaka et al., 1995) . Therefore, assessment of relationships between p16 expression and TRK/Ha-ras expression would further help in determining the relationship between p16 expression and N-myc ampli®cation. Although the age of children at diagnosis is also a factor to predict the outcome of patients with neuroblastoma, we found no correlation between loss of p16 expression and the age of patients. Thus, loss of p16 expression would be a prognostic factor independently of age of patients. Since loss of p16 expression signi®cantly correlated with 9p LOH and methylation of the p16 gene, it is likely that allelic loss and methylation would be important and direct mechanisms for inactivation of the p16 gene in neuroblastoma. However, we found no relationships between 9p LOH and methylation of the p16 gene. Thus, the remaining wild type p16 allele is not hypermethylated in the tumors with 9p LOH. This result suggests that LOH with methylation is not a common mechanism for inactivation of the p16 gene in neuroblastoma. Since there were a number of p16-negative tumors without 9p LOH and/or methylation of the p16 gene, other genetic mechanisms for inactivation of p16 expression would exist in neuroblastoma.
The INK4a locus encodes two unrelated proteins, p16 and p19 ARF and both of these proteins are capable of inducing cell cycle arrest (Quelle et al., 1995) . To elucidate whether the p19 ARF gene are involved in the genesis and/or progression of neuroblastoma, we examined 19 neuroblastoma cell lines for expression of the p19 ARF gene by RT ± PCR analysis and for mutation of this gene by PCR ± SSCP analysis. p19 ARF expression was detected in 11 cell lines and not detected in the remaining eight cell lines. Mutations of the p19 ARF gene were not detected in these cell lines (data not shown). Thus, although it is possible that the p19 ARF gene is also involved in the growth regulation of neuroblastoma cells, the role of the p19 ARF gene in the genesis and/or progression of neuroblastoma still remains unclari®ed.
In conclusion, it was demonstrated here that abnormal DNA methylation was a direct mechanism for inactivation of p16 expression in neuroblastoma, and that restoration of p16 expression was sucient to suppress the growth of neuroblastoma cells in vitro. Furthermore, loss of p16 expression was signi®cantly associated with prognosis of patients with neuroblastoma independently of N-myc ampli®cation. Thus, the p16 gene would be a tumor suppressor gene involved in the progression of neuroblastoma.
Materials and methods
Cell lines and primary tumors
Fifteen neuroblastoma cell lines, NB1, NB9, NB16, NB19, NB39, NB69, LAN2, LAN5, KP-N-NS, IMR-32, SCMCN4, SCMCN5, GOTO, LAN1 and TGW were used in this study. We previously reported that the p16 gene is not expressed in these cell lines except LAN1 and TGW (Takita et al., 1997) . Cells were maintained in RPMI 1640 (Nissui) medium supplemented with 10% fetal calf serum (FCS) in a humidi®ed atmosphere containing 5% CO 2 at 378C. Tumors were obtained from 74 patients admitted to Saitama Children's Medical Center and National Kure Hospital between May 1983 and June 1996. Paran embedded tumor tissues were used for immunohistochemical analysis. The patients were staged according to the classi®cation of staging in neuroblastoma (Evans et al., 1971) . Of the 74 cases, 18 were classi®ed as being stage I, 19 as II, 13 as III, 18 as IV and six as IVS. Thirty-®ve patients were found by mass screening program. Information about the genotype of N-myc was available in 68 cases, and the presence of 9p LOH in tumors was previously de®ned in 38 cases (Takita et al., 1997) . Nmyc was ampli®ed in six of the 68 cases, and 9p LOH was detected in 12 of the 38 cases. Patients with stage I, II or IVS were treated with either surgery alone or surgery plus chemotherapy consisting of vincristin and cyclophosphamide with or without radiotherapy. Patients with stage III or IV were treated with multidrug chemotherapy consisting of cyclophosphamide, adriamycin, cisplatin and etoposide with or without surgery and radiotherapy.
5-aza-2-deoxycytidine treatment 5-aza-2-deoxycytidine (Sigma Chemical) was dissolved in cold RPMI 1640 immediately before use. Cells were exposed to 0.5 and 1.0 mM of 5-aza-2-deoxycytidine for 3 days, with the medium and drug being replaced in every 24 h (Merlo et al., 1995; Otterson et al., 1995) . Then cells were harvested and used for Western blot analysis.
Transfection NB19, NB69 and LAN2 cells were transfected with the pCDKN2WT or P114L vector using the lipofection method (Gibco BRL-Life Technologies). 6610 5 cells were seeded into a 100 mm dish and incubated in 8 ml of Opti-MEM (Gibco) with 20 ml lipofectin and 1.37 pmol of the expression vector. Twelve hours after transfection, Opti-MEM was replaced by the 8 ml of the medium supplemented with 20% FCS. Cells were harvested 48 h after transfection. Wild-type and mutant p16 expression vectors, pCDKN2WT and P114L, were obtained from Dr H-J Su Huang (Arap et al., 1995 (Arap et al., , 1997 . The P114L mutant, containing the point mutation at codon 114, was proved to be functionally impaired (Arap et al., 1997) .
Western blot analysis
Cellular protein was extracted by lysing 1610 6 cells with 40 ml of lysis buer (50 mM HEPES-NaOH, pH 7.0, 1% Nonidet P-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1 mM dithiothreitol, 1 mM PMSF and 50 mg/ml aprotinin). Fifty mg of protein was separated in a 4 ± 20% gradient sodium dodecyl sulfate (SDS)/polyacrylamide gel and electroblotted to Hybond-Enhanced Chemiluminescence (ECL) nitrocellulose membrane (Amersham). After being blocked with 5% nonfat dry milk and 0.1% Tween 20 in Tris-buered saline, membranes were incubated at 378C for 2 h with the 1 : 400 dilution of a rabbit polyclonal anti-p16 antibody (PharMingen). The blot was subsequently probed by the ECL Western blotting detection system (Amersham Corp., Arlington Heights, IL). Equal loading of protein was con®rmed by staining the membrane after detection.
Flow cytometric analysis of the cell cycle
At 48 h post transfection, cells were harvested and ®xed in 10 ml of 50% ethanol for at least 30 min at 48C, and reacted with a rabbit polyclonal anti-p16 antibody (PharMingen). Cells were incubated with a goat antirabbit FITC-conjugated secondary antibody (Jackson Labs). Following incubation, cells were treated with 5 mg/ml RNAase A, and to stain DNA, 0.1 mg/ml propidium iodide (Sigma) was added to the cells. Samples were then analysed using¯ourescene-activated cell sorter (FACS) (Becton Dickenson, San Jose, CA, USA). Twoparameter analysis was carried out with the¯ow cytometer and the proportions of cells in G 0 /G 1 , S and G 2 /M phases of the cell cycle were determined. The eect of exogenous p16 expression on the cell cycle distribution of neuroblastoma cell lines were determined by measuring the DNA contents of transfected cells, through staining with propidium iodide. FACS pro®les of cells were calculated using the CellQuest and Modi®t Lt software.
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Immunohistochemistry
Paran blocks containing tumors were sectioned at 4 mM, axed to silane-coated glass slides. Sections were dewaxed in xylene and rehydrated through descending graded ethanol and endogenous peroxidase activity was quenched in 3% H 2 O 2 in methanol for 10 min at room temperature. The slides were then rinsed in ethanol and rehydrated. Before immunostaining for p16 protein, the slides were boiled in a microwave pressure cooker with 0.01 M sodium phosphate-citrate buer, pH 8.0 at 908C for 5 *10 min as a antigen retrieval step, and then left to cool for 15 min. After rinsing in phosphate buered saline (PBS), pH 7.4, non-speci®c antibody binding was reduced by incubating the sections with 10% normal horse serum in PBS for 30 min. After decanting excess serum, sections were incubated overnight at 48C with the JC8 anti-p16 mouse monoclonal antibody (Burns et al., 1998) at 1 : 500 dilution. As a negative control, the primary antibody was replaced with bovine serum albumin. Following washing, the slides were incubated with a biotinylated horse anti-mouse IgG for 30 min and then with a 1 : 100 dilution of the avidinebiotinyl-peroxidase complex (VECTASTAIN, Vector Laboratorises, Inc., Burlingame, CA, USA) for further 30 min. After washing in PBS, the peroxidase was visualized with 0.02% 3,3'-diaminobenzidine tetrahydrochloride containing 0.005% H 2 O 2 in 50 mM ammonium acetate-citric acid buer, pH 6.0. Finally the sections were counterstained lightly with hematoxylin. Four neuroblastoma cell lines, LAN1, TGW, LAN2 and NB69, were used as controls for immunohistochemical analysis, since we previously showed that p16 mRNA and p16 protein was detected in LAN1 and TGW and not detected in LAN2
and NB69 by Northern and Western blot analyses, respectively (Takita et al., 1997) . These cell lines were harvested, washed in PBS, and ®xed in 10% buered formalin for 24 h at 48C. After ®xation, cells were embedded in paran according to the standard procedures. Paran blocks containing the cells were further processed for immunohistochemistry as described above.
Statistical analysis
Signi®cance of the dierences in immunohistochemical results and various biological and clinical features of the disease among the patient group was examined by Fishers exact test. The vital status of the patients was observed until March 31, 1997. The survival curves for each group of the patients were estimated by the Kaplan ± Meier method, and the resulting curves were compared using the log rank test for univariate analysis. Multivariate analysis was performed using the Cox proportional hazards model and stepwise Cox regression model.
